One of the current limitations of adenoviral gene therapy is a vector-induced humoral immune response that blocks effective re-administration of the vector. In an animal model of the inborn error of urea synthesis ornithine transcarbamylase (OTC) deficiency, the sparse fur (spf/y) mouse, we tested a strategy to transiently block the CD4 mediated immune response at the time of virus administration using an anti-CD4 monoclonal antibody (GK1.5). The co-administration of GK1.5 resulted in a significantly diminished production of neutralizing antibody to the adenovirus vector, but minimally prolonged metabolic correction. A second infusion of the same virus in GK1.5 treated spf/y mice led to a complete normalization of liver OTC activity at day 3 after infection and a significant metabolic correction of urinary orotate and plasma glutamine. In contrast, there was no evidence of enhanced OTC expression or metabolic correction (measured by normalization of plasma glutamine and urinary
Introduction
E1-deleted adenoviruses have been widely used as an effective vector for somatic gene transfer into a variety of tissues. 1, 2 The application of these vectors, however, has been limited by cellular immune responses to both viral and transgene products which often leads to the elimination of virus containing cells. [3] [4] [5] [6] [7] Moreover, the generation of antiviral neutralizing antibodies following the initial exposure to virus will further prevent the readministration of adenovirus of the same serotype. 6, 8 This limitation is particularly problematic in the treatment of inborn errors of metabolism such as cystic fibrosis (CF) or ornithine transcarbamylase (OTC) deficiency where repeated therapies are required to obtain life-long genetic reconstitution. Several strategies have been developed to circumvent the humoral immune responses to adenovirus vectors. Mack et al 9 have demonstrated that anti-orotate) after the second infusion of virus in spf/y mice not treated with GK1.5. Furthermore, when co-administered with two consecutive doses of adenovirus, the anti-CD4 treatment allowed improved transgene expression upon a third administration of virus and a partial normalization of the metabolic abnormalities, compared with mice that did not receive anti-CD4 treatment. The level of OTC expression from the third viral infusion, however, was lower than that from the second viral infusion. Passive transfer experiments suggest that low levels of neutralizing antibodies developing over repeated viral administration was the likely cause of the reduced transgene expression. Together, these findings demonstrated that the host immune system can be modulated to permit effective transgene expression at therapeutic levels by re-administered adenoviral vectors. Gene Therapy (2000) 7, 1761-1767.
adenovirus neutralizing immunity can be bypassed by using adenoviral vectors of alternative serotypes. The duration of transgene expression, however, was reduced compared with that in naive animals due to the development of cellular immune response to viral gene products. Dai et al 10 have shown that adenovirus-mediated gene expression can be stabilized using immune suppressors such as cyclosporine and cyclophosphamide which inhibit both humoral and cellular immune responses. It was later shown by Jooss et al 11 that transient cyclophosphamide treatment prevented formation of neutralizing antibody to adenovirus and allowed successful re-administration of adenovirus in mouse liver and lung. Monoclonal antibodies specific to molecules important for immune recognition, such as CD8, TCR and CD40 ligand, have also been utilized to block virus-induced immune responses.
12-14 Recent studies in mouse models have shown that the activation of CD4-positive T cells by viral capsid proteins is a necessary step in both CTL-mediated clearance of virus-containing cells and production of antiadenovirus neutralizing antibodies. 15 It has been reported that a single dose of an anti-CD4 antibody (GK1.5), given 24 h before adenovirus administration, resulted in pro- longed transgene expression in mouse liver. 16 Our group has also reported that the same antibody, given at a 3-day interval before and after viral administration, blocked antiviral neutralizing antibody production and allowed efficient transgene expression from a second or even a third viral vector in mouse lung 15 or liver, 17 respectively. In this study, we have further evaluated the effectiveness of the anti-CD4 treatment in a therapeutic setting using an animal model of the inborn error of urea synthesis, OTC deficiency. OTC deficiency often leads to life-threatening episodes of hyperammonemia in early childhood. 18 In an animal model of OTC deficiency, the spf/y mouse, this deficiency is associated with a 20-fold elevation of urinary orotate and a doubling of plasma glutamine. 19 Recently, we have demonstrated that intravenous infusion of recombinant adenoviruses carrying mouse OTC cDNA effectively corrected these metabolic abnormalities in spf/y mice for up to 60 days. 19 The virus-treated animals, however, developed high titers of neutralizing antibodies and became resistant to subsequent doses of virus. We report here that anti-CD4 treatment with GK1.5 prevented the development of anti-adenovirus neutralizing antibody in spf/y mouse and permitted successful metabolic correction with re-administered adenoviral vectors. We demonstrated, however, that low titers of neutralizing antibody may still develop over repeated viral administration and reduce the effectiveness of later viral administration.
Results
Anti-CD4 treatment suppresses development of adenovirus-specific neutralizing antibodies As illustrated in Figure 1 , three groups of spf/y mice were injected intravenously with an adenovirus carrying mouse OTC cDNA (Ad.CMVmOTC, 1 × 10 11 particles per mouse). Groups 2 and 3 also received intraperitoneal injections of GK1.5 at a dose of 100 g per mouse at day −3, 0, 3 and 6 relative to the time of viral infusion. OTC expression in these animals was monitored by biweekly measurements of urinary orotates and plasma glutamine levels. On day 70, when OTC expression from the first viral infusion had decreased to undetectable levels, all three groups of mice received a second dose of virus (Ad.CMVmOTC, 1 × 10 11 particles per mouse). This time, only group 3 received anti-CD4 treatment with the viral infusion. OTC expression from the second viral infusion was again monitored by metabolic measurements. On day 140, a third dose of virus (Ad.CMVmOTC, 1 × 10 11 particles per mouse) was given to group 2 and 3, and the transgene expression followed by metabolic measurements. During the course of three independent experiments, two mice from each group were killed 3 days after each viral infusion for liver OTC activity assays.
To determine the effectiveness of anti-CD4 treatment in blocking the production of neutralizing antibody to adenovirus, plasma samples were taken and analyzed for neutralizing antibodies to adenovirus from all three groups of mice at day 28 and 98, ie 4 weeks after the first or second viral infusion, respectively ( Figure 2 ). At day 28, mice received virus with no anti-CD4 treatment (group 1) developed anti-adenovirus neutralizing antibodies with a mean titer of 154 ± 100 (mean ± s.e.m. of 14 observations). Mice that received anti-CD4 treatment with viral infusion (groups 2 and 3) had no detectable levels of plasma anti-adenovirus antibody (47 observations). Upon re-administration of the virus, animals in group 1 showed a significant increase in antiadenovirus antibody titer to a mean value of 3840 ± 1810 (mean ± s.e.m. of five observations), while mice that received anti-CD4 treatment with the first but not the second viral infusion developed a low level of neutralizing antibody (titer = 213 ± 168, mean ± s.e.m. of 12 observations, group 2). Neutralizing antibody was detected, however, only in one (titer = 320) of the 18 animals that received anti-CD4 treatment with both viral infusions (group 3).
Anti-CD4 treatment allows repeated metabolic correction of OTC deficiency in spf/y mice with adenoviral vectors Adenovirus-mediated OTC expression in spf/y mice should result in lower levels of urinary orotates and plasma glutamine as a result of normalized ureagenesis in liver. As shown in Figure 3 , the first viral infusion led to a significant reduction of urinary orotates and plasma glutamine in all three groups of mice. The metabolic correction lasted for about 3 weeks and gradually returned to baseline, presumably due to the loss of virus-infected hepatocytes. One goal of this study was to determine if preventing the development of anti-adenovirus antibodies was associated with a prolonged efficacy of the adenoviral vector. To develop a measure that should correlate with the duration, the data for correction of orotate were examined in each individual animal. First, the time required to achieve maximal correction was compared in animals that had received GK1.5 with the first injection of adenovirus (groups 2 and 3) to animals that had received control injections with the first dose of adenovirus (group 1). There was no significant difference in the time required to achieve maximal correction of orotate in these two groups of animals (group 1, 18.7 ± 2 days, n = 12; groups 2 and 3, 20.1 ± 1.5 days, n = 30, P = 0.56). The data for each animal were then examined to determine when the orotate level had increased to 50% of the pre-adenoviral values. There was a significant difference between the two groups of animals with this measure (group 1, 32.2 ± 1.7 days, n = 12; groups 2 and 3, 38.1 ± 1.5 days, n = 30, P Ͻ 0.02), but the biological significance of this modestly prolonged metabolic correction remains to be addressed.
The second goal of this study was to determine if blockade of neutralizing antibodies permitted re-administration of the adenoviral vector. In mice that did not receive anti-CD4 treatment (group 1), the second viral infusion resulted in no OTC expression as measured by OTC lysate assay (data not shown) and histochemical staining at day 3 after viral administration. However, a significant reduction in urine orotates and plasma glutamine were achieved with the re-administered virus in mice that received anti-CD4 treatment with the first viral infusion, ie those that had no detectable neutralizing antibody after first viral infusion (groups 2 and 3). Upon the third viral infusion, only those mice that received anti-CD4 treatment with both first and second viral infusion (group 3) showed a reduction in plasma glutamine levels ( Figure 3 ). Transgene expression in these mice was further confirmed by histochemical analysis of OTC activity from liver samples taken 3 days after each viral infusion (Figure 4 ).
Low titers of anti-adenovirus neutralizing antibody develops over repetitive viral administration Although no neutralizing antibody was detected by the neutralizing antibody assay in mice that received two consecutive infusions of adenovirus with anti-CD4 treatment ( Figure 2, group 3) , histochemical analysis of liver samples from these mice revealed significantly decreased OTC expression 3 days after the third viral infusion in contrast to that after the first or second infusion (Figure 4 , group 3). Since the minimal dilution in our neutralizing antibody assay was 1:20, it was possible that low levels of anti-adenovirus neutralizing antibodies may still develop with repeated viral administrations despite anti-CD4 treatment that accompanied each viral infusion. To test this possibility, whole plasma was collected from mice in each experimental group at day 98. Samples from the
Figure 4 Cytochemical demonstration of OTC activity in liver tissues from spf/y mice infused with recombinant adenovirus. Spf/y mice were killed 3 three days after the first, second or third virus infusion. Liver tissues were analyzed for OTC activity by histochemical staining. Representative photomicrographs are presented. Magnification ×100.
same group were pooled and divided into two aliquots. The first aliquot was directly transferred into naive C3H mice intravenously through the retro-orbital plexus of veins. The second aliquot was subjected to a protein G Sepharose column purification. The flow-through and eluant from the column (IgG fraction of plasma) were collected, dialyzed against PBS, and transferred into naive C3H mice. All recipient animals were then injected with a LacZ containing recombinant adenovirus (Ad.CMVLacZ, 5 × 10 10 particles per mouse) 1 h after the passive transfer. The mice were killed 3 days later and were analyzed for ␤-galactosidase expression in liver. Whole plasma from mice in group 3 blocked viral gene expression in recipient animals. Moreover, the component(s) that blocked ␤-galactosidase expression resided in the IgG fraction of the plasma ( Figure 5 ). We therefore concluded that low levels of neutralizing antibody were present in plasma from group 3 mice. To further evaluate the efficacy of GK1.5 treatment in depleting CD4
+ lymphocytes, the abundance of CD4
+ cells in blood were measured in spf/y mice before and after the treatment. It appeared that there was a fraction of CD4
+ cells, about 40% of the total CD4 + cell population in spf/y mice (on C3HeB/J background), that was resistant to GK1.5 treatment (Table 1) , although the same treatment regimen effectively deleted Ͼ99% of the CD4 + cells in C57BL/6 mice. A higher dose of GK1.5 (200 g/ml) did not result in any improvement in the depletion of CD4 + cells in spf/y mice. Western blot analysis also failed to detect any anti-GK1.5 antibody in GK1.5-treated spf mice, although it is difficult to interpret a negative result (data not shown).
Discussion
Host immune response to adenovirus and virus-infected cells has become a major obstacle to the successful application of somatic gene therapy using adenoviral vectors. A number of studies have demonstrated that a cellular immune response, which is dependent on MHC class I restricted presentation of newly synthesized antigens, is mostly responsible for the destruction of virus-transduced cells, and therefore, the loss of transgene expression. [3] [4] [5] 7 In addition, a humoral immune response, which is induced by the input viral capsid proteins, would effectively block virus entry upon a second infection. 9, 17 Although new generations of adenoviral vectors developed in our laboratory and others have been rendered more deficient in expression of viral proteins and elicit less virus-specific cytotoxic T-lymphocytes (CTLs), they would still trigger a humoral immune response. The strategy applied in this study was to block the development of neutralizing antibodies by transiently inactivating all CD4-positive cells using a depleting anti-CD4 monoclonal antibody GK1.5, an approach that can be tested in patients with a humanized version of blocking antibody. It has been reported that the antibody was capable of both prolonging adenovirus-mediated LacZ expression and inhibiting the formation of neutralizing antibodies in mice. 15, 17 The purpose of this study was to test the anti-CD4 treatment in a therapeutic setting where the effectiveness of the treatment is measured not only by transgene expression but also by the metabolic correction of the enzyme deficiency as a result of transgene expression. 25.8 ± 6.5
Spf/y mice were treated with GK1.5 as described in Materials and methods. Blood samples were taken the day before and 2 days after the treatment for FACS analysis. Values shown are mean ± S.D. of eight determinations.
In considering the approach for treating a truly chronic disease with frequent repeated administration of a transiently expressing vector, one must critically evaluate its performance. There is no doubt that one can inhibit a primary response to allow full re-administration. Inhibition of CD4 T cells at the time of the second viral administration, however, appears to be less efficient, which results in the development of low levels of neutralizing antibodies. This may be problematic for liver gene transfer with vectors administered via the circulation but is unlikely to affect re-administration to other organs where vector is directly injected to the target site.
Gene Therapy
Why is there low level neutralizing antibody found in the presence of pharmacologic inhibition of CD4 and can it be avoided? Experiments in immune-deficient mice indicate that the B cell response is totally T cell-dependent for adenoviral vectors, suggesting the inhibition of T cells may not be sufficient. 3 This is consistent with the partial depletion of CD4 + cells in the spf/y mice on the C3HeB/J background. Moreover, the failure to completely deplete CD4 + T cells can also lead to the production of anti-idiotypic antibody to GK1.5. Although we could not detect antibody to GK1.5 in these mice by Western blot, it is still possible that the level of antiidiotypic antibody is simply below the detection limit. These may be remedied by more potent pharmacologic inhibition. Alternatively, the presentation of antigen may have persisted beyond the duration of T cell inhibition, a situation which could be handled by extending the pharmacologic therapy.
In summary, our results confirm, in a relevant preclinical model of gene therapy for a liver metabolic disease, the potential of transient immune blockade for vector re-administration. The GK1.5 treatment is transient but effective in blocking the production of neutralizing antibody to adenovirus. However, our results also indicate the accumulative effect of immune activation, and the impact of genetic composition on the effectiveness of immune suppression. Strategies must be developed to assure complete inhibition of T cell activation if multiple re-administrations are contemplated. Moreover, most anti-CD4 antibodies that have been approved for human use are non-depleting. The effectiveness of this class of antibodies in attenuating humoral immune responses to adenovirus in humans still needs to be evaluated.
Materials and methods

Mice
Spf and control mice were originally purchased from Jackson Laboratory (Bar Harbor, ME, USA) and were bred into C3HeB/J (also from Jackson Laboratory) background for more than 20 generations in the Wistar animal facility. Female heterozygous spf/x mice were bred with normal male (x/y) C3HeB/J mice to generate experimental spf/y mice. All animals used in the experiment were within 6 to 10 weeks of age.
Vector construction and administration E1-deleted recombinant adenovirus carrying E2a ts125 temperature sensitive mutation and mouse OTC cDNA (Ad.CMVmOTC) was constructed and propagated as described. 19 Virus stock was diluted with sterile PBS to a final concentration of 1 × 10 12 particles per ml and injected into recipient animals through the tail vein (100 l per mouse).
Anti-CD4 treatment GK1.5, a rat anti-mouse CD4 monoclonal antibody, was produced in ascites and purified by a Protein G column (Pharmacia, Uppsala, Sweden). Animals receiving the treatment were given GK1.5 four times i.p. at a dose of 100 g per mouse at day −3, 0, 3 and 6 relative to the time of viral infusion.
OTC histochemistry and metabolic measurements
Histochemical analysis of OTC activity on sections of mouse liver was performed as described by Ye et al. 19 Plasma and urine samples were collected at day −3, day −1, and at different time-points after virus infusion. Determination of urine orotates and plasma glutamine was performed as described by Ye et al. 19 Adenovirus-specific neutralizing antibody assay Mouse plasma samples were incubated at 56°C for 30 min to inactivate complement and then diluted in DMEM containing 10% FBS in two-fold steps starting from 1:20. Each serum dilution (100 l) was mixed with 100 l of DMEM containing 10% FBS and 1 × 10 4 particles of adenovirus (sub360), incubated for 1 h at 37°C, and applied to 80% confluent HeLa cells in 96-well plates (2 × 10 4 cells per well). After 3 days at 37°C, cells were fixed and stained with ultra-violet blue. The titer of neutralizing antibody of each sample was reported as the highest dilution with which less than 50% of cells remained in the well.
Passive transfer
Plasma samples (400 l) harvested from donor animals were loaded on to a 1 ml Sepharose G column. The flowthrough was collected. The column was then washed with 10 ml of 20 mm Na-phosphate, pH 7.0, and eluted with 400 l of 100 mm glycine-HCl, pH 2.7. The eluant was collected in an Eppendorf tube containing 20 l of 1 m Tris-HCl, pH 7.0 and was dialyzed against 2 liters of PBS at 4°C for 3 h. 200 l of the flow-through or dialyzed eluant (mouse IgG) were transferred into naive C3H mouse via the retro-orbital plexus of veins. One hour later, 50 l of LacZ virus (Ad.CMVLacZ, 1 × 10 12 particles per ml) in PBS was infused into the tail vein. Liver tissues were analyzed for ␤-galactosidase expression by X-gal histochemistry 3 days later.
Fluorescence activated cell sorting (FACS) analysis of blood lymphocytes Whole blood (100 l) was obtained by retro-orbital bleeding. The heparinized blood sample was mixed with 5 l each of FITC-conjugated anti-CD4 antibody, PE-conjugated anti-CD8 antibody and Cy5-conjugated anti-CD3 antibody, and was incubated at room temperature for 30 min. Erythrocytes were lysed by adding 900 l of FACS lysing solution (Becton Dickinson, San Jose, CA, USA) to the mixture and incubation on ice for 5 min. The lymphocytes were washed with PBS twice and resuspended in 1% paraformaldehyde for quantitative analysis by FACS (Becton Dickinson).
